BiotechTube

lysozyme 90 mg + Placebo

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Chronic Obstructive Pulmonary Disease

Conditions

Chronic Obstructive Pulmonary Disease, Asthma

Trial Timeline

Oct 1, 2012 → Jan 1, 2014

NCT ID
NCT01715493

About lysozyme 90 mg + Placebo

lysozyme 90 mg + Placebo is a approved stage product being developed by Eisai for Chronic Obstructive Pulmonary Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01715493. Target conditions include Chronic Obstructive Pulmonary Disease, Asthma.

What happened to similar drugs?

20 of 20 similar drugs in Chronic Obstructive Pulmonary Disease were approved

Approved (20) Terminated (3) Active (0)
✅Pegasys® + Pegasys®Chugai PharmaceuticalApproved
✅Telmisartan/Rosuvastatin 40/10mg + Telmisartan 40mgYuhanApproved
✅placebo + aspirin + clopidogrel + aspirin OR prasugrel + aspirinDaiichi SankyoApproved
✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
✅alefaceptAstellas PharmaApproved
✅AlefaceptAstellas PharmaApproved
✅lorcaserin + phentermine placebo + lorcaserin + phentermine-HCl + phentermine placebo + lorcaserin + phentermine-HClEisaiApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01715493ApprovedCompleted

Competing Products

20 competing products in Chronic Obstructive Pulmonary Disease

See all competitors
ProductCompanyStageHype Score
Levofloxacin 500Dr. Reddy's LaboratoriesPre-clinical
23
mRNA-0184ModernaPhase 1
0
Lubiprostone + Lubiprostone + PlaceboDr. Reddy's LaboratoriesPhase 3
37
macitentan 10 mgBML, Inc.Phase 3
32
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
29
TERN-701Terns PharmaceuticalsPhase 1/2
36
Fludarabine + Cyclophosphamide + PRGN-3007PrecigenPhase 1
23
LY3556050 + PlaceboEli LillyPhase 2
35
THB001Third Harmonic BioPhase 1
11
BriquilimabJasper TherapeuticsPhase 1/2
26
BriquilimabJasper TherapeuticsPhase 1/2
14
BriquilimabJasper TherapeuticsPhase 2
29
Empagliflozin + Matching placeboEli LillyPhase 3
40
LY3461767 + PlaceboEli LillyPhase 1
29
Pirtobrutinib + Venetoclax + RituximabEli LillyPhase 3
44
LY3526318 + PlaceboEli LillyPhase 2
35
PirtobrutinibEli LillyPhase 2
42
Ibrutinib + LY3214996Eli LillyPhase 1
21
Pirtobrutinib + AcalabrutinibEli LillyPhase 2
27
LYR-210Lyra TherapeuticsPhase 2
25